# Praxis (PRAX) — News

PRAX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/prax/news

## Recent headlines

- [LPL Financial Holdings Inc.: TD Cowen raises target price to $380 from $377](https://www.ainvest.com/news/lpl-financial-holdings-td-cowen-raises-target-price-380-377-2610) — AInvest Wire, Oct 12, 2026
  TD Cowen has raised its target price for LPL Financial Holdings Inc. (Nasdaq: LPLA) to $380 from $377, reflecting the firm’s ongoing strategic initiatives and operational performance. The adjustment comes amid continued growth in client assets and advisor onboarding, with LPL Financial reporting…
- [Praxis Precision Medicines, Inc.: Jonestrading raises target price to $534 from $441](https://www.ainvest.com/news/praxis-precision-medicines-jonestrading-raises-target-price-534-441-2610) — AInvest Wire, Oct 2, 2026
  Jonestrading has revised its target price for Praxis Precision Medicines, Inc. (PRAX) to $534 from $441, reflecting a positive outlook on the stock . This adjustment aligns with broader analyst sentiment, as 20 Wall Street analysts have issued ratings for PRAX over the past 12 months, resulting in…
- [Praxis Precision Medicines, Inc.: Raymond James raises target price to $945 from $765](https://www.ainvest.com/news/praxis-precision-medicines-raymond-james-raises-target-price-945-765-2608) — AInvest Wire, Aug 17, 2026
  Praxis Precision Medicines (NASDAQ:PRAX) recently received a significant update from Raymond James Financial, which raised its price target for the stock to $945 from $765, maintaining a "Strong Buy" rating in its latest research report. This adjustment reflects the firm's continued confidence in…
- [Perceptive Advisors exits drug, BLTE, EVMN, NMRA in 2Q: 13F](https://www.ainvest.com/news/perceptive-advisors-exits-drug-blte-evmn-nmra-2q-13f-2608) — AInvest Wire, Aug 14, 2026
  Perceptive Advisors LLC, a biotech-focused investment firm, disclosed its second-quarter 2026 portfolio changes in a recent 13F filing. The firm exited several positions, including drugmaker Belite Bio (BLTE), Evommune (EVMN), and Neumora Therapeutics (NMRA), as part of its strategic rebalancing…
- [Praxis Precision Medicines, Inc. announces inducement grants under Nasdaq listing rule 5635(c)(4)](https://www.ainvest.com/news/praxis-precision-medicines-announces-inducement-grants-nasdaq-listing-rule-5635-4-2607) — AInvest Wire, Jul 2, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).